These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9695192)

  • 1. Design and analysis for survival data under order restrictions with a modified logrank test.
    Liu PY; Tsai WY; Wolf M
    Stat Med; 1998 Jul; 17(13):1469-79. PubMed ID: 9695192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and analysis of multiarm clinical trials with survival endpoints.
    Liu PY; Dahlberg S
    Control Clin Trials; 1995 Apr; 16(2):119-30. PubMed ID: 7789135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
    Royston P; B Parmar MK
    Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring a three-armed clinical trial with survival endpoints: Fisher's least significant difference approach.
    Chen PL; Dominik R
    J Biopharm Stat; 2004 Aug; 14(3):791-801. PubMed ID: 15468765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of survival distributions in clinical trials: A practical guidance.
    Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
    Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graphical displays for clarifying how allocation ratio affects total sample size for the two sample logrank test.
    Saville BR; Kim YS; Koch GG
    Pharm Stat; 2011; 10(1):40-4. PubMed ID: 20077513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation study and implementation of the tests based on weighted Turnbull's estimators for interval-censored data.
    Chi Y
    Stat Med; 2001 Jan; 20(2):281-94. PubMed ID: 11169602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of two-part models with competitors.
    Lachenbruch PA
    Stat Med; 2001 Apr; 20(8):1215-34. PubMed ID: 11304737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unobserved covariates in the two-sample comparison of survival times: a maximum efficiency robust test.
    Broët P; Moreau T; Lellouch J; Asselain B
    Stat Med; 1999 Jul; 18(14):1791-800; discussion 1801. PubMed ID: 10407249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size calculation for the augmented logrank test in randomized clinical trials.
    Hattori S; Komukai S; Friede T
    Stat Med; 2022 Jun; 41(14):2627-2644. PubMed ID: 35319100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating significance level and power comparisons for testing multiple endpoints in clinical trials.
    Gong J; Pinheiro JC; DeMets DL
    Control Clin Trials; 2000 Aug; 21(4):313-29. PubMed ID: 10913807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
    Royston P; Parmar MK
    Trials; 2014 Aug; 15():314. PubMed ID: 25098243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A computer program for sample size and power calculations in the design of multi-arm and factorial clinical trials with survival time endpoints.
    Natarajan R; Turnbull BW; Slate EH; Clark LC
    Comput Methods Programs Biomed; 1996 Mar; 49(2):137-47. PubMed ID: 8735021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing sample size formulae for trials with unbalanced allocation using the logrank test.
    Hsieh FY
    Stat Med; 1992 Jun; 11(8):1091-8. PubMed ID: 1496196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An asymptotic analysis of the logrank test.
    Strawderman RL
    Lifetime Data Anal; 1997; 3(3):225-49. PubMed ID: 9384654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum information designs.
    Lachin JM
    Clin Trials; 2005; 2(5):453-64. PubMed ID: 16315649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.